Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Taylor

Showing results (101-110 of 246) with videos related to

Pageof 25
Sort By:
British Journal of Clinical Pharmacology|June 5, 2023
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trialLine Uhrenholt, Kirsten Duch, Robin Christensen, et al.
Journal of Autoimmunity|November 2, 2005
Anti-TNF therapy: where have we got to in 2005?Marc Feldmann, Fionula M Brennan, Brian M J Foxwell, et al.
Seminars in Arthritis and Rheumatism|January 7, 2021
The Jak/STAT pathway: A focus on pain in rheumatoid arthritisLee S Simon, Peter C Taylor, Ernest H Choy, et al.
BMJ Open|February 17, 2022
Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisationsKayoko Kaneko, Daniel Prieto-Alhambra, Clare Jacklin, et al.
Clinical and Experimental Rheumatology|October 19, 2021
The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cellsSam Weston, Joanne L Macdonald, Lynn M Williams, et al.
RMD Open|February 22, 2023
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritisMaxime Dougados, Peter C Taylor, Clifton O Bingham, et al.
Rheumatology and Therapy|April 14, 2026
Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World SettingPeter C Taylor, Aditi Kadakia, Jack Milligan, et al.
Pathology|April 15, 2020
A simple and expedient PCR format for rapid molecular screening of methicillin-resistant Staphylococcus aureus in Amies gel swabsChristopher J McIver, Ranapanada Nilushika D De Silva, Noel Er, et al.
RMD Open|December 11, 2021
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to targetPeter C Taylor, Mart Van de Laar, Andrew Laster, et al.
Plos One|September 12, 2015
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological StudyAnton Wulf Christensen, Simon Tarp, Daniel E Furst, et al.
Pageof 25

Showing results (101-110 of 246) with videos related to

Sort By:
Pageof 25
British Journal of Clinical Pharmacology|June 5, 2023
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trialLine Uhrenholt, Kirsten Duch, Robin Christensen, et al.
Journal of Autoimmunity|November 2, 2005
Anti-TNF therapy: where have we got to in 2005?Marc Feldmann, Fionula M Brennan, Brian M J Foxwell, et al.
Seminars in Arthritis and Rheumatism|January 7, 2021
The Jak/STAT pathway: A focus on pain in rheumatoid arthritisLee S Simon, Peter C Taylor, Ernest H Choy, et al.
BMJ Open|February 17, 2022
Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisationsKayoko Kaneko, Daniel Prieto-Alhambra, Clare Jacklin, et al.
Clinical and Experimental Rheumatology|October 19, 2021
The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cellsSam Weston, Joanne L Macdonald, Lynn M Williams, et al.
RMD Open|February 22, 2023
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritisMaxime Dougados, Peter C Taylor, Clifton O Bingham, et al.
Rheumatology and Therapy|April 14, 2026
Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World SettingPeter C Taylor, Aditi Kadakia, Jack Milligan, et al.
Pathology|April 15, 2020
A simple and expedient PCR format for rapid molecular screening of methicillin-resistant Staphylococcus aureus in Amies gel swabsChristopher J McIver, Ranapanada Nilushika D De Silva, Noel Er, et al.
RMD Open|December 11, 2021
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to targetPeter C Taylor, Mart Van de Laar, Andrew Laster, et al.
Plos One|September 12, 2015
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological StudyAnton Wulf Christensen, Simon Tarp, Daniel E Furst, et al.
Pageof 25